Eli Lilly and Incyte's eczema treatment delayed at FDA – again

The two pharmaceutical companies have been forced to announce that the FDA's processing of Olumiant as a treatment for atopic dermatitis has been delayed for a second time. This is due to questions surrounding the drug class.

Photo: Mike Blake/REUTERS / X00030

The US Food and Drug Administration, FDA, has again postponed its deadline for responding to Eli Lilly's application for the authorization of Olumiant, which is an eczema treatment for adults.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs